ValiRx - Re: VAL Stream Log - Beaufort Securities's note out this...

Beaufort Securities's note out this morning on Research Tree: "There is little doubt about the Company's enthusiasm for the continuing safety results for VAL 201, with no significant adverse events being reported. Early indications of efficacy have also been shown. Following the promising pre-clinical evidence of the compound's effect on endometriosis the Company is continuing the design of the protocol for this indication and to test VAL201 for its in-human potential in the treatment of this debilitating female condition. The protocol and associated partnerships - both commercial and technical - are expected to be in place before the final reporting of the current 'safety and tolerability-focused' clinical trial. Indeed, the opportunity for developing and exploiting the compound for a further indication in the treatment of endometriosis or hormone induced abnormal cell growth in women, via partnering and collaboration, is similarly fast approaching and the necessary preparatory steps and conversations are underway. Scientific progress has included the manufacture of clinical grade VAL401 capsule and this production is a crucial step in VAL401's progression towards the dosing phase of its clinical trial. A second US patent – in this case covering the use of the VAL401 formulation as a treatment for adenocarcinoma - has been allowed by the US patent office. With this patent providing IP protection in the largest oncology market in the world, ValiSeek consider this patent to be a substantial asset, both validating and underpinning ValiSeek's potential future valuation."